212 related articles for article (PubMed ID: 29556960)
1. Comprehensive Physicochemical and Biological Characterization of the Proposed Biosimilar Darbepoetin Alfa, LBDE, and Its Originator Darbepoetin Alfa, NESP
Jeong YR; Jeong RU; Son JH; Kwon JC; Jung S; Song MA; Hwang JA; Lee GM
BioDrugs; 2018 Apr; 32(2):153-168. PubMed ID: 29556960
[TBL] [Abstract][Full Text] [Related]
2. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical and biological evaluation of JR-131 as a biosimilar to a long-acting erythropoiesis-stimulating agent darbepoetin alfa.
Tani J; Ito Y; Tatemichi S; Yamakami M; Fukui T; Hatano Y; Kakimoto S; Kotani A; Sugimura A; Mihara K; Yamamoto R; Tanaka N; Minami K; Takahashi K; Hirato T
PLoS One; 2020; 15(4):e0231830. PubMed ID: 32302352
[TBL] [Abstract][Full Text] [Related]
4. Mass spectrometric characterisation of darbepoetin alfa biosimilars with C-terminal arginine residues.
Okano M; Sato M; Kageyama S
Drug Test Anal; 2016 Nov; 8(11-12):1138-1146. PubMed ID: 27706921
[TBL] [Abstract][Full Text] [Related]
5. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
Cerutti ML; Pesce A; Bès C; Seigelchifer M
BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214
[TBL] [Abstract][Full Text] [Related]
6. An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.
Gianoncelli A; Bonini SA; Bertuzzi M; Guarienti M; Vezzoli S; Kumar R; Delbarba A; Mastinu A; Sigala S; Spano P; Pani L; Pecorelli S; Memo M
BioDrugs; 2015 Aug; 29(4):285-300. PubMed ID: 26334631
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Pharmacokinetic-Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers.
Kim S; Hong T; Ko JW; Huh W; Kim JR
BioDrugs; 2019 Feb; 33(1):101-112. PubMed ID: 30506495
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept.
Cho IH; Lee N; Song D; Jung SY; Bou-Assaf G; Sosic Z; Zhang W; Lyubarskaya Y
MAbs; 2016; 8(6):1136-55. PubMed ID: 27246928
[TBL] [Abstract][Full Text] [Related]
9. Physicochemical characterization of Remsima.
Jung SK; Lee KH; Jeon JW; Lee JW; Kwon BO; Kim YJ; Bae JS; Kim DI; Lee SY; Chang SJ
MAbs; 2014; 6(5):1163-77. PubMed ID: 25517302
[TBL] [Abstract][Full Text] [Related]
10. Comparative Assessment of the Effect of Hyper-glycosylation on the Pattern and Kinetics of Degradation of Darbepoetin Alfa using a Stability-Indicating Orthogonal Testing Protocol.
Moenes EM; Al-Ghobashy MA; Mohamed AA; Salem MY
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1072():405-414. PubMed ID: 29157782
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Pharmacokinetic, Pharmacodynamic and Tolerability Profiles of CKD-11101, Darbepoetin Alfa (NESP
Jeon I; Oh J; Kwon YK; Yoon SH; Cho JY; Jang IJ; Yu KS; Lee S
Drug Des Devel Ther; 2021; 15():1735-1747. PubMed ID: 33953543
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of CKD-11101 (darbepoetin-alfa proposed biosimilar) compared with NESP in anaemic chronic kidney disease patients not on dialysis.
Lee JH; Ha Chung B; Joo KW; Shin SK; Kim YL; Na KY; Do JY; Park SK; Shin BC; Lee JS; Kim YW; Kim SW; Lee KW; Kang GW; An WS; Shin GT; Han S; Yang CW
Curr Med Res Opin; 2019 Jun; 35(6):1111-1118. PubMed ID: 30569763
[TBL] [Abstract][Full Text] [Related]
13. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.
Egrie JC; Dwyer E; Browne JK; Hitz A; Lykos MA
Exp Hematol; 2003 Apr; 31(4):290-9. PubMed ID: 12691916
[TBL] [Abstract][Full Text] [Related]
14. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.
Sörgel F; Schwebig A; Holzmann J; Prasch S; Singh P; Kinzig M
BioDrugs; 2015 Apr; 29(2):123-31. PubMed ID: 25837839
[TBL] [Abstract][Full Text] [Related]
15. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab.
Schreiber S; Yamamoto K; Muniz R; Iwura T
Pharmacol Res Perspect; 2020 Jun; 8(3):e00604. PubMed ID: 32500668
[TBL] [Abstract][Full Text] [Related]
16. Glycan analysis of erythropoiesis-stimulating agents.
Cowper B; Lavén M; Hakkarainen B; Mulugeta E
J Pharm Biomed Anal; 2020 Feb; 180():113031. PubMed ID: 31838284
[TBL] [Abstract][Full Text] [Related]
17. Mass spectrometric glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC/ESI-MS.
Harazono A; Hashii N; Kuribayashi R; Nakazawa S; Kawasaki N
J Pharm Biomed Anal; 2013 Sep; 83():65-74. PubMed ID: 23708432
[TBL] [Abstract][Full Text] [Related]
18. In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate.
Chen L; Wang L; Shion H; Yu C; Yu YQ; Zhu L; Li M; Chen W; Gao K
MAbs; 2016 Oct; 8(7):1210-1223. PubMed ID: 27380163
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Structural, Biological, and Functional Similarity of Biosimilar Granulocyte Colony Stimulating Factor to its Reference Product.
Bor Tekdemir Z; Seckin AI; Kacar T; Yilmaz E; Bekiroglu S
Pharm Res; 2020 Oct; 37(11):215. PubMed ID: 33026512
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept.
Montacir O; Montacir H; Springer A; Hinderlich S; Mahboudi F; Saadati A; Parr MK
Protein J; 2018 Apr; 37(2):164-179. PubMed ID: 29411222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
